We're killing ourselves, says Jamie Lee Curtis

Back in 2002, photographs of a somewhat plump Jamie Lee Curtis appeared in many popular magazines. At the time, Curtis was just two years into pursuing sobriety and had gained upwards of 20 pounds. It appeared Curtis was flaunting her new look, perhaps even giving the public permission to be happy in their own skin. Not a bad thing, right?

It was a bad idea, says Curtis who now regrets communicating to the masses that letting yourself go is OK. Because it's not. Now fit and trim -- not skinny, just trim -- Curtis says in the July 2007 issue of Ladies Home Journal, "So I think what some people took from those photos was: Love yourself, no matter what. And the problem with this is: What if what you're doing is unhealthy?"

"And the problem is that how many of us are killing ourselves every day? Who here has high blood pressure and is still eating salt and French fries? Who has been told that her liver is enlarged and unless she stops drinking she's gonna end up with liver disease and/or need a liver transplant? We create senseless acts of violence against ourselves every day. And we live in this amnesia that we're not."

New drug combo fights certain breast cancers

On Tuesday, researchers announced that a three-drug cocktail may help women with HER2-positive breast cancer better than any other drug used on its own. About one quarter of women with breast cancer make up this HER2 category.

Tests on mice revealed using the three drugs along with breast cancer drug tamoxifen helped wipe out tumors altogether. And the tumors did not come back. This is the first time mice were cured of a very aggressive human breast tumor. Incidentally, when a single drug was used, tumors returned within several weeks.

The three wonder drugs used in this study -- all are monoclonal antibodies that precisely target certain aspects of tumors -- are the experimental drug pertuzumab; trastuzumab, also known as Herceptin; and gefitinib, or Iressa.

Published in the Journal of the National Cancer Institute, this study supports the notion that HER2-positive tumors eventually become resistant to one drug and attacking them on several fronts seems to work better.